<DOC>
	<DOCNO>NCT01596855</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety FG-4592 maintaining and/or correct hemoglobin ( Hb ) give subject End Stage Renal Disease ( ESRD ) maintenance hemodialysis receive epoetin alfa .</brief_summary>
	<brief_title>Study FG-4592 Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis China</brief_title>
	<detailed_description>Dose range study three consecutive dose escalation cohort . The study objective demonstrate FG-4592 effective maintaining hemoglobin ( Hb ) level convert epoetin alfa establish optimum start dos dose adjustment regimen Hb maintenance .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Subject voluntarily sign date informed consent form 2 . Age 18 75 year 3 . Endstage renal disease ( ESRD ) receive maintenance hemodialysis TIW ≥4 month prior Day 1 4 . Hemoglobin ( Hb ) value 4 screen visit mean Hb must 9.0 12.0 g/dL ( inclusive ) , difference must ≤1.5 g/dL . 5 . Stable dos IV Subcutaneous injection epoetin alfa , define follow : Epoetin alfa dose range 6 week prior Day 7 : 3000 20,000 IU/week Stable dos epoetin alfa ( i.e. , maximum epoetin alfa dose exceed 130 % low dose epoetin alfa take period ) 6 . Complete Blood Count ( CBC ) , Hematology , liver function blood test within acceptable limit 7 . Serum folate vitamin B12 level low limit normal ( LLN ) 8 . Body weight : 40 100 kg ( dry weight ) inclusive 9 . Body mass index ( BMI ) : 16 38 kg/m2 inclusive 10 . HD subject : dialysis vascular access via native arteriovenous fistula synthetic graft ( via catheter ) 1 . Anticipated change hemodialysis prescription access screen dose period study 2 . Any clinically significant infection evidence underlie infection white blood cell count ( WBC ) &gt; ULN screen two separate occasion , 3 . Positive following : human immunodeficiency virus ( HIV ) ; hepatitis B surface antigen ( HBsAg ) ; antihepatitis C virus antibody ( antiHCV Ab ) 4 . History chronic liver disease 5 . New York Heart Association Class III IV congestive heart failure 6 . Chronic inflammatory disease glomerulonephritis could impact erythropoiesis ( e.g. , systemic lupus erythematosis , rheumatoid arthritis , celiac disease ) even currently remission 7 . Active chronic gastrointestinal bleeding , know coagulation disorder 8 . Hemoglobinopathy ( e.g. , homozygous sicklecell disease , thalassemia type , etc . ) 9 . Hematological disorder , include myelodysplastic syndrome , multiple myeloma , pure red cell aplasia 10 . History hemosiderosis , hemochromatosis , polycystic kidney disease , anephric 11 . Active hemolysis diagnosis hemolytic syndrome 12 . Known bone marrow fibrosis 13 . Uncontrolled symptomatic secondary hyperparathyroidism ( PTH &gt; 600ng/L ) 14 . Any prior organ transplantation 15 . Drugtreated gastroparesis , shortbowel syndrome , gastrointestinal condition may lead reduce absorption study drug 16 . History alcohol drug abuse ; positive drug screen substance prescribe subject 17 . Prior treatment FG4592 18 . Use traditional Chinese medicine ( TCM ) screen visit Day 1 plan use TCM study unless approve advance Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Renal</keyword>
</DOC>